A cost-effectiveness analysis of the EAST – AFNET 4 trial indicated the health benefits of early rhythm control come at reasonable additional costs compared to usual care.
Sicker patients in the EAST-AFNET4 trial showed a pronounced survival advantage from early rhythm control, compared with a rate-control-first approach, while those with fewer comorbidities missed out.